IRON Stock Analysis: Disc Medicine | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.333m USD | 12M Return: -12.3% | US2546041011 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.6M
Warnings
Tailwinds
Seasonality 6.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on discovering, developing, and commercializing novel therapies for serious hematologic diseases. Founded in 2017 and publicly listed since 2020, the company operates within the biotechnology sub-industry of the healthcare sector, a segment characterized by high research and development costs, long product development timelines, and value driven largely by pipeline progress and regulatory milestones rather than recurring revenue. Disc Medicines portfolio targets fundamental biological pathways involved in red blood cell formation-primarily heme biosynthesis and iron homeostasis-an approach that distinguishes it from competitors focused on broader oncology or immunology indications. Its pipeline spans both clinical and preclinical stages, including bitopertin for erythropoietic porphyrias and Diamond-Blackfan anemia, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, DISC-3405 for polycythemia vera and other hematologic disorders, and the preclinical program DISC-0998 targeting anemia in inflammatory diseases. As a clinical-stage biotech, the companys valuation is closely tied to the advancement of these candidates through clinical trials and potential regulatory approvals rather than commercial product sales.
- Bitopertin Phase 3 data readout in erythropoietic porphyrias
- DISC-0974 anemia trial results in myelofibrosis and CKD
- Cash burn and potential equity offering pressure shares
| Net Income: -245.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -8.71 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 > 3% & CFO -197.5m > Net Income -245.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.7m) vs 12m ago 10.45% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: -1.71% > 50% (prev 0.0%; Δ -1.71% > 0%) |
| Interest Coverage Ratio: -68.14 > 6 (EBIT TTM -242.0m / Interest Expense TTM 3.55m) |
| A: 0.96 (Total Current Assets 732.8m - Total Current Liabilities 30.4m) / Total Assets 735.1m |
| B: -0.86 (Retained Earnings -633.2m / Total Assets 735.1m) |
| C: -0.35 (EBIT TTM -242.0m / Avg Total Assets 700.1m) |
| D: 7.09 (Book Value of Equity 644.2m / Total Liabilities 90.9m) |
| Altman-Z'' = 8.58 = AAA |
As of October 11, 2026, the stock is trading at USD 62.06 with a total of 675,132 shares traded. Over the past week, the price has changed by -3.80%, over one month by -18.89%, over three months by -21.38% and over the past year by -12.28%.
Current recommended Stop Loss: 56.30 (which is 9.3% or 2 ATR below the current price).
Disc Medicine has received a consensus analysts rating of 4.92. Therefore, it is recommended to buy IRON.
- StrongBuy: 12
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 103.2 | 66.2% |
P/B = 3.9378
Revenue TTM = -12.0m USD
EBIT TTM = -242.0m USD
EBITDA TTM = -241.7m USD
Long Term Debt = 59.3m USD (from longTermDebt, last quarter)
Short Term Debt = 315k USD (from shortTermDebt, last quarter)
Debt = 62.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.52m
Net Debt = -642.6m USD (calculated: Debt 62.4m - CCE 705.0m)
Enterprise Value = 1.69b USD (2.33b + Debt 62.4m - CCE 705.0m)
Interest Coverage Ratio = -68.14 (Ebit TTM -242.0m / Interest Expense TTM 3.55m)
EV/FCF = -8.45x (Enterprise Value 1.69b / FCF TTM -200.1m)
FCF Yield = -11.84% (FCF TTM -200.1m / Enterprise Value 1.69b)
WARNING: Negative Revenue TTM = -12.0m
FCF Margin = 1.67k% (FCF TTM -200.1m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Net Margin = 2.05k% (Net Income TTM -245.9m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Gross Margin = unknown ((Revenue TTM -12.0m - Cost of Revenue TTM 281k) / Revenue TTM)
Tobins Q-Ratio = 2.30 (Enterprise Value 1.69b / Total Assets 735.1m)
Interest Expense / Debt = 5.69% (Interest Expense 3.55m / Debt 62.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -191.2m (EBIT -242.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.70 (Total Current Assets 732.8m / Total Current Liabilities 37.2m)
Debt / Equity = 0.10 (Debt 62.4m / totalStockholderEquity, last quarter 644.2m)
Debt / EBITDA = 2.66 (negative EBITDA) (Net Debt -642.6m / EBITDA -241.7m)
Debt / FCF = 3.21 (negative FCF - burning cash) (Net Debt -642.6m / FCF TTM -200.1m)
Total Stockholder Equity = 661.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.12% (Net Income -245.9m / Total Assets 735.1m)
RoE = -37.17% (Net Income TTM -245.9m / Total Stockholder Equity 661.5m)
RoCE = -33.58% (EBIT -242.0m / Capital Employed (Equity 661.5m + L.T.Debt 59.3m))
RoIC = -27.12% (negative operating profit) (NOPAT -191.2m / Invested Capital 705.0m)
WACC = 9.61% (E(2.33b)/V(2.40b) * Re(9.75%) + D(62.4m)/V(2.40b) * Rd(5.69%) * (1-Tc(0.21)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.18 | Cagr: 21.83%
[DCF] Fair Price = unknown (Cash Flow -200.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.71 | Chg30d=+1.60% | Revisions=+0% | Analysts=9
EPS current Year (2026-12-31): EPS=-6.56 | Chg30d=+1.67% | Revisions=+40% | GrowthEPS=-9.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-7.08 | Chg30d=+2.48% | Revisions=+40% | GrowthEPS=-7.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +44% (up=5, down=1)